Literature DB >> 16553520

Warfarin and royal jelly interaction.

Nancy J Lee1, Joli D Fermo.   

Abstract

An 87-year-old African-American man came to the internal medicine clinic for a routine anticoagulation management visit. He had no complaints. His medical history was significant for stage IV-A follicular non-Hodgkin's lymphoma, atrial fibrillation, and hypertension. His long-term drug therapy consisted of warfarin, felodopine, lisinopril-hydrochlorothiazide, controlled-release diltiazem, potassium chloride, and oxycodone. He reported adherence with his prescribed drugs and denied taking any over-the-counter or herbal products. Overall, the patient's drug therapy had been consistent during the preceding 3 months, no significant changes had occurred in his clinical status, and no significant changes had been noted in his diet; his international normalized ratio (INR) had ranged from 1.9-2.4 (therapeutic range 2-3). He denied tobacco use, alcohol consumption, and recent travel. Four weeks later, the patient came to the emergency department with hematuria. He denied dysuria, taking more than the prescribed amount of warfarin, any changes in his diet, taking any over-the-counter or herbal products, and any other bleeding. On admission to the hospital, his INR was 6.88, which increased to 7.29 during his hospital stay. On further investigation, the patient admitted that he had started taking an herbal supplement, royal jelly, 1 week earlier. When asked specifically about the ingredients in the supplement, he stated that royal jelly was the only component. Relative to the patient's denial of any other changes in his condition or drug regimen, the most probable explanation for his elevated INR and subsequent bleeding is a possible interaction between royal jelly and warfarin. To our knowledge, no case reports concerning royal jelly and warfarin taken concomitantly have been reported. Clinicians should be proactive and repeatedly provide education regarding the potential dangers of dietary supplements taken with conventional drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16553520     DOI: 10.1592/phco.26.4.583

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

Review 1.  Critical evaluation of causality assessment of herb-drug interactions in patients.

Authors:  Charles Awortwe; Memela Makiwane; Helmuth Reuter; Christo Muller; Johan Louw; Bernd Rosenkranz
Journal:  Br J Clin Pharmacol       Date:  2018-01-29       Impact factor: 4.335

Review 2.  Acute liver injury following Garcinia cambogia weight-loss supplementation: case series and literature review.

Authors:  Giada Crescioli; Niccolò Lombardi; Alessandra Bettiol; Ettore Marconi; Filippo Risaliti; Michele Bertoni; Francesca Menniti Ippolito; Valentina Maggini; Eugenia Gallo; Fabio Firenzuoli; Alfredo Vannacci
Journal:  Intern Emerg Med       Date:  2018-05-25       Impact factor: 3.397

3.  The efficacy of topical royal jelly on healing of diabetic foot ulcers: a double-blind placebo-controlled clinical trial.

Authors:  Mansour Siavash; Saeideh Shokri; Sepehr Haghighi; Mohammad Ali Shahtalebi; Ziba Farajzadehgan
Journal:  Int Wound J       Date:  2013-04-08       Impact factor: 3.315

4.  The efficacy of topical Royal Jelly on diabetic foot ulcers healing: A case series.

Authors:  Mansour Siavash; Saeideh Shokri; Sepehr Haghighi; Mahbubeh Mohammadi; Mohammad Ali Shahtalebi; Ziba Farajzadehgan
Journal:  J Res Med Sci       Date:  2011-07       Impact factor: 1.852

5.  Influence of andrographolide on the pharmacokinetics of warfarin in rats.

Authors:  Xiaoli Zhang; Xiaosu Zhang; Xiaocui Wang; Meijun Zhao
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

Review 6.  Royal Jelly-A Traditional and Natural Remedy for Postmenopausal Symptoms and Aging-Related Pathologies.

Authors:  Andreea Bălan; Marius Alexandru Moga; Lorena Dima; Sebastian Toma; Andrea Elena Neculau; Costin Vlad Anastasiu
Journal:  Molecules       Date:  2020-07-20       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.